$CUE
Cue Biopharma Inc

2023 Q4 Form 10-Q Financial Statement

#000095017023058838 Filed on November 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $1.821M $2.100M
YoY Change 1104.13% 2988.24%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.609M $3.650M
YoY Change 24.45% 3.46%
% of Gross Profit
Research & Development $10.89M $9.874M
YoY Change -3.93% 30.42%
% of Gross Profit
Depreciation & Amortization $116.0K $128.0K
YoY Change -42.92% -35.35%
% of Gross Profit
Operating Expenses $15.50M $13.52M
YoY Change 3.06% 21.8%
Operating Profit -$11.42M
YoY Change 3.52%
Interest Expense $398.0K $254.0K
YoY Change 36.28% 104.84%
% of Operating Profit
Other Income/Expense, Net $414.0K
YoY Change 444.74%
Pretax Income -$13.43M -$11.01M
YoY Change -7.94% 0.5%
Income Tax
% Of Pretax Income
Net Earnings -$13.43M -$11.01M
YoY Change -7.94% 0.46%
Net Earnings / Revenue -737.73% -524.05%
Basic Earnings Per Share -$0.24
Diluted Earnings Per Share -$0.28 -$0.24
COMMON SHARES
Basic Shares Outstanding 45.12M 44.96M
Diluted Shares Outstanding 46.36M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.51M $54.69M
YoY Change -36.41% -7.59%
Cash & Equivalents $48.51M $54.69M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $1.242M $1.200M
YoY Change 47.64% -30.27%
Inventory
Prepaid Expenses
Receivables $1.698M $1.661M
Other Receivables $0.00 $0.00
Total Short-Term Assets $51.45M $57.52M
YoY Change -33.34% -6.78%
LONG-TERM ASSETS
Property, Plant & Equipment $7.118M $1.064M
YoY Change 374.77% -35.2%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.958M $120.0K
YoY Change 2204.94% -8.4%
Total Long-Term Assets $10.08M $11.37M
YoY Change -28.52% -22.12%
TOTAL ASSETS
Total Short-Term Assets $51.45M $57.52M
Total Long-Term Assets $10.08M $11.37M
Total Assets $61.53M $68.89M
YoY Change -32.59% -9.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.501M $2.480M
YoY Change 28.19% 21.27%
Accrued Expenses $7.505M $5.127M
YoY Change 111.16% 32.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due $3.963M $4.000M
YoY Change 98.15% 300.0%
Total Short-Term Liabilities $17.08M $17.21M
YoY Change 47.91% 68.33%
LONG-TERM LIABILITIES
Long-Term Debt $4.202M $5.160M
YoY Change -47.7% -42.62%
Other Long-Term Liabilities $3.162M $3.900M
YoY Change -47.45% -38.3%
Total Long-Term Liabilities $7.364M $5.160M
YoY Change -8.35% -42.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.08M $17.21M
Total Long-Term Liabilities $7.364M $5.160M
Total Liabilities $24.45M $26.22M
YoY Change -4.51% 2.69%
SHAREHOLDERS EQUITY
Retained Earnings -$301.2M -$287.8M
YoY Change 20.26% 22.0%
Common Stock $338.3M $330.4M
YoY Change 6.97% 15.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.09M $42.67M
YoY Change
Total Liabilities & Shareholders Equity $61.53M $68.89M
YoY Change -32.59% -9.71%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$13.43M -$11.01M
YoY Change -7.94% 0.46%
Depreciation, Depletion And Amortization $116.0K $128.0K
YoY Change -42.92% -35.35%
Cash From Operating Activities -$10.96M -$7.800M
YoY Change 4.25% 13.52%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities $2.000K $5.000M
YoY Change -99.96% -116.98%
Cash From Investing Activities $2.000K $5.000M
YoY Change -99.96% -116.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.780M 4.590M
YoY Change -82.56% -51100.0%
NET CHANGE
Cash From Operating Activities -10.96M -7.800M
Cash From Investing Activities 2.000K 5.000M
Cash From Financing Activities 4.780M 4.590M
Net Change In Cash -6.179M 1.790M
YoY Change -128.23% -104.92%
FREE CASH FLOW
Cash From Operating Activities -$10.96M -$7.800M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$10.96M -$7.800M
YoY Change 4.24% 14.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001645460
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38327
dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2680
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45123281
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54691000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51614000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1661000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
57000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1165000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
841000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
57517000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
77187000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1064000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1499000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7060000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9203000
CY2023Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2977000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3116000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
120000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128000
CY2023Q3 us-gaap Assets
Assets
68888000
CY2022Q4 us-gaap Assets
Assets
91283000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2480000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2731000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5127000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3554000
CY2023Q3 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
2238000
CY2022Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
0
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3399000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3300000
CY2023Q3 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
1963000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17207000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11548000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3855000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6017000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5160000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8035000
CY2023Q3 us-gaap Liabilities
Liabilities
26222000
CY2022Q4 us-gaap Liabilities
Liabilities
25600000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45123281
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45123281
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43042548
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43042548
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
45000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
330376000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
316192000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-0
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-96000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-287755000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250456000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
42666000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
65683000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
68888000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91283000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2100000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3669000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1094000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3645000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3528000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12071000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12465000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9874000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7571000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29915000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27246000
CY2023Q3 cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
CY2022Q3 cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
258000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
13519000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11099000
us-gaap Operating Expenses
OperatingExpenses
41986000
us-gaap Operating Expenses
OperatingExpenses
39453000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11419000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11031000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38317000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38359000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
700000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
200000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1756000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
296000
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-286000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-124000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-738000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-355000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
414000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
76000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1018000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-59000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11005000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10955000
us-gaap Net Income Loss
NetIncomeLoss
-37299000
us-gaap Net Income Loss
NetIncomeLoss
-38418000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-92000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
96000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-92000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11000000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11047000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37203000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38510000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46358555
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46358555
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35383430
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35383430
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45274124
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45274124
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34471499
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34471499
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
59756000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2064000
CY2022Q3 cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-9000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-92000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10955000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
50764000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
46004000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5589000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2073000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
5000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11005000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
42666000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16598000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7384000
cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-200000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-92000
us-gaap Net Income Loss
NetIncomeLoss
-38418000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
50764000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
65683000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7605000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6108000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
473000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
96000
us-gaap Net Income Loss
NetIncomeLoss
-37299000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
42666000
us-gaap Profit Loss
ProfitLoss
-37299000
us-gaap Profit Loss
ProfitLoss
-38418000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
443000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
719000
us-gaap Share Based Compensation
ShareBasedCompensation
6108000
us-gaap Share Based Compensation
ShareBasedCompensation
7384000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
2142000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
507000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
0
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
258000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-234000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-101000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
21000
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
98000
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
76000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1603000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2347000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
324000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
846000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
139000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-395000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-251000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-546000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1573000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-741000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
2238000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-645000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2064000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-397000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
3000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29003000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31292000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-25000000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
0
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
29445000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25002000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29609000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
7605000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
16598000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
cue Payment Of Term Loan
PaymentOfTermLoan
-1000000
cue Payment Of Term Loan
PaymentOfTermLoan
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
473000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
142000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
200000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7078000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26256000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3077000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34645000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51764000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64521000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
54841000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29876000
us-gaap Interest Paid Net
InterestPaidNet
768000
us-gaap Interest Paid Net
InterestPaidNet
354000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9057000
cue Operating Lease Modification
OperatingLeaseModification
0
cue Operating Lease Modification
OperatingLeaseModification
7119000
CY2023Q3 us-gaap Marketable Securities
MarketableSecurities
54691000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
cue Pre Funded Warrants
PreFundedWarrants
1531440
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18220326
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7058087
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
54691000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
45423000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
24675000
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54691000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
45423000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2023Q3 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2022Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
24771000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
96000
CY2022Q4 us-gaap Debt Securities Trading And Available For Sale
DebtSecuritiesTradingAndAvailableForSale
24675000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
24771000
CY2022Q4 us-gaap Debt Securities Held To Maturity Threshold Period Past Due
DebtSecuritiesHeldToMaturityThresholdPeriodPastDue
P12M
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
96000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5699000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5741000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4635000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4242000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1064000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1499000
CY2023Q3 us-gaap Depreciation
Depreciation
128000
CY2022Q3 us-gaap Depreciation
Depreciation
198000
us-gaap Depreciation
Depreciation
434000
us-gaap Depreciation
Depreciation
630000
cue Amortization Of Trademark
AmortizationOfTrademark
9000
cue Amortization Of Trademark
AmortizationOfTrademark
9000
cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
80000
CY2023Q3 cue Cash Obligation
CashObligation
20000000
CY2023Q3 us-gaap Interest Expense
InterestExpense
254000
us-gaap Interest Expense
InterestExpense
848000
CY2022Q3 us-gaap Interest Expense
InterestExpense
33000
us-gaap Interest Expense
InterestExpense
98000
CY2023Q3 us-gaap Interest Expense Other
InterestExpenseOther
183000
us-gaap Interest Expense Other
InterestExpenseOther
354000
CY2022Q3 us-gaap Interest Expense Other
InterestExpenseOther
33000
us-gaap Interest Expense Other
InterestExpenseOther
76000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1000000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4000000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
9000000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
5000000
CY2023Q3 cue Accretion Of Final Payment
AccretionOfFinalPayment
207000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-46000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5160000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
4000000
CY2023Q3 us-gaap Deferred Finance Costs Current Gross
DeferredFinanceCostsCurrentGross
37000
CY2023Q3 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
141748
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
28000
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
21000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0416
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9703
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.104
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0292
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.921
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.957
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6173867
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.6
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10719846
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2576900
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.65
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
165602
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1084685
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.78
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7500480
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.4
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4365960
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M14D
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12141000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13856000
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2023Q3 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
10.38
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2073000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2064000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6108000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7384000
cue Number Of Tranches
NumberOfTranches
1
CY2023Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2015-06-15
cue Pre Funded Warrants
PreFundedWarrants
1531440
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10719846
cue Class Of Warrants Or Rights Cashless Issue Exercises
ClassOfWarrantsOrRightsCashlessIssueExercises
0
cue Class Of Warrant Or Right Number Of Securities Withheld
ClassOfWarrantOrRightNumberOfSecuritiesWithheld
0
CY2020Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1250000
CY2021Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
122000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
402000
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
146000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
309000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
835000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3368000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2799000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
818000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
7820000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
566000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7254000
CY2023Q3 cue Operating Leases Rent Expense
OperatingLeasesRentExpense
853000
CY2022Q3 cue Operating Leases Rent Expense
OperatingLeasesRentExpense
860000
cue Operating Leases Rent Expense
OperatingLeasesRentExpense
2566000
cue Operating Leases Rent Expense
OperatingLeasesRentExpense
3309000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
709000
us-gaap Operating Lease Payments
OperatingLeasePayments
2064000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
853000
us-gaap Operating Lease Cost
OperatingLeaseCost
2566000
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0575
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M20D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M20D

Files In Submission

Name View Source Status
0000950170-23-058838-index-headers.html Edgar Link pending
0000950170-23-058838-index.html Edgar Link pending
0000950170-23-058838.txt Edgar Link pending
0000950170-23-058838-xbrl.zip Edgar Link pending
cue-20230930.htm Edgar Link pending
cue-20230930.xsd Edgar Link pending
cue-ex10_1.htm Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img77026815_0.jpg Edgar Link pending
img77026815_1.jpg Edgar Link pending
img77026815_2.jpg Edgar Link pending
img77026815_3.jpg Edgar Link pending
img77026815_4.jpg Edgar Link pending
img77026815_5.jpg Edgar Link pending
img77026815_6.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
cue-20230930_cal.xml Edgar Link unprocessable
cue-20230930_def.xml Edgar Link unprocessable
cue-20230930_lab.xml Edgar Link unprocessable
cue-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cue-20230930_htm.xml Edgar Link completed
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending